SynthesisJournal of cardiothoracic surgery2025
Concomitant tricuspid surgery for moderate tricuspid regurgitation improves survival in left-sided valve surgery - a meta-analysis.
Synthesis in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Price of Redo Mitral Valve Replacement: Determinants of Major Adverse Postoperative Events.Journal of cardiovascular development and disease · 2026Article
- Endoscopic Minimally Invasive Beating-Heart Tricuspid Valve Surgery Without Jugular Vein Cannulation or Caval Snaring: Clinical Outcomes Using Novel Percutaneous Venous Cannulation.Medicina (Kaunas, Lithuania) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThere is controversy over the optimal management of moderate tricuspid valve regurgitation during left-sided valve surgery due to the paucity of robust evidence for enhanced outcomes from concomitant tricuspid valve repair. Hence, we assessed the literature to compare clinical outcomes in patients undergoing left-sided valve procedures either with or without tricuspid valve repair surgery.
methodsWe performed a literature search using MEDLINE, EMBASE, Scopus and Web of Science. We identified articles to evaluate primary outcomes of both, cardiac and overall mortality. Secondary outcomes included stroke, wound infection, reoperation, new-onset atrial fibrillation, renal failure, duration of intensive care stay and permanent pacemaker implantation. All analysis was done using the random effects model.
resultsA total of 36 studies were included with 76,249 patients. There was significant reduction in cardiac mortality (p < 0.0001) with concomitant tricuspid valve repair despite higher CPB (p < 0.00001) and X-Clamp times (p < 0.00001). There was no significant difference in overall mortality. There was significantly lower postoperative tricuspid regurgitation (p < 0.00001) with concomitant tricuspid repair. There were no differences in postoperative stroke, wound infection, atrial fibrillation, renal failure, and intensive care unit duration of stay between the two groups.
conclusionsConcomitant tricuspid valve surgery for moderate tricuspid regurgitation during left-sided valve surgery offers improved survival benefit due to significant decrease in cardiac mortality. Additionally, this strategy results in significant decrease in late tricuspid regurgitation with no increase in morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.